Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2017, Vol. 44 Issue (4): 611-612    DOI: 10.12891/ceog3940.2017
Case Report Previous articles | Next articles
Marked improvement of severe gastroparesis following high dosage, but very well tolerated, dextroamphetamine sulfate
J. H. Check1, *(), R. Cohen2
1 Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, NJ, USA
2 Cooper Institute for Reproductive and Hormonal Disorders, P.C., Mt. Laurel, NJ, USA
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  Purpose: To determine if treatment with dextroamphetamine sulfate could provide palliation for severe treatment refractory gastroparesis. Materials and Methods: Dextroamphetamine sulfate 15 immediate release tablets were initiated and the dose titrated upwards according to the degree of improvement vs. side effects. Results: The large majority of the symptoms of abdominal pain, very severe vomiting, and diarrhea was markedly improved but it took a very high dosage of amphetamine salts (150 mg). This dosage, however, did not cause any side effects. Conclusions: The gynecologist, who also is frequently asked to evaluate gastrointestinal (GI) symptomatology, is more cognizant of the increased cellular permeability syndrome, and thus may be called upon to treat certain GI conditions that should be more appropriate for the GI specialist to treat. The more articles that appear in the literature, the better the chance to promulgate the knowledge of these conditions, e.g., gastroparesis, to other specialties.
Key words:  Gastroparesis      Increased cellular permeability syndrome      Dextroamphetamine sulfate      Sympathomimetic amines     
Published:  10 August 2017     
*Corresponding Author(s):  J.H. CHECK     E-mail:  laurie@ccivf.com

Cite this article: 

J. H. Check, R. Cohen. Marked improvement of severe gastroparesis following high dosage, but very well tolerated, dextroamphetamine sulfate. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(4): 611-612.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog3940.2017     OR     https://ceog.imrpress.com/EN/Y2017/V44/I4/611

[1] J.H. Check, D. Check, R. Cohen. A novel effective treatment for menière’s disease – dextroamphetamine sulfate[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 807-809.
[2] J.H. Check, D. Check. The increased cellular permeability syndrome manifesting as severe idiopathic type urinary incontinence[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 812-814.
[3] J.H. Check, R. Cohen. Sympathomimetic amine therapy abrogates severe long-term unexpalined abdominal pain and diarrhea (microscopic colitis) - possible infertility implications[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 489-491.
[4] J.H. Check, D.L. Check, M.P. Dougherty. Marked improvement of the aromatase induced arthralgia syndrome following treatment with dextroamphetamine sulfate[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 291-292.
[5] J.H. Check, M.P. Dougherty, D.L. Check. Long standing post-herpetic neuralgia resistant to standard anti-neuropathy medication showing quick dramatic improvement following treatment with sympathomimetic amines[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 335-336.
[6] J.H. Check, M. Citerone, T. Citerone. The increased cellular permeability syndrome as a cause of traumatic stuttering[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 773-774.
[7] J.H. Check. Changing the name of a syndrome: sympathetic neural hyperalgesia edema syndrome becomes – the increased cellular permeability syndrome[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 819-823.
[8] J.H. Check, R. Cohen. Amelioration of severe generalized idiopathic pruritus in an estrogen deficient woman taking an aromatase inhibitor for breast cancer following treatment with amphetamine salts[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(6): 934-935.
[9] J.H. Check, A. Jaffe. Dextroamphetamine sulfate provided quick relief of severe post-partum depression that was recalcitrant to standard antidepressants and psychotherapy[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(2): 272-274.
[10] J.H. Check. Chronic unremitting lower abdominal pain quickly abrogated following treatment with amphetamine[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(1): 109-111.
[11] J.H. Check. Dextroamphetamine sulfate treatment eradicates long-term chronic severe headaches from temporomandibular joint syndrome - a case that emphasizes the role of the gynecologist in treating headaches in women[J]. Clinical and Experimental Obstetrics & Gynecology, 2016, 43(1): 119-122.
[12] J.H. Check, A. Jaffe. Resolution of pelvic pain related to adenomyosis following treatment with dextroamphetamine sulfate[J]. Clinical and Experimental Obstetrics & Gynecology, 2015, 42(5): 671-672.
[13] J.H. Check, R. Cohen. Complete resolution of frozen shoulder syndrome in a woman treated with dextroamphetamine sulfate for chronic urinary urgency[J]. Clinical and Experimental Obstetrics & Gynecology, 2015, 42(5): 679-680.
[14] J. H. Check, R. Cohen. An update on the treatment of female alopecia and the introduction of a potential novel therapy[J]. Clinical and Experimental Obstetrics & Gynecology, 2015, 42(4): 411-415.
[15] J.H. Check, A. Whetstone. Failed surgical therapy for chronic back pain and sciatica may be due to hypofunction of the sympathetic nervous system[J]. Clinical and Experimental Obstetrics & Gynecology, 2015, 42(4): 529-530.
No Suggested Reading articles found!